MGMT and central nervous system cancer: Isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion status, and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation have all been well demonstrated to relate with the malignancy of gliomas.